Merck, Teva End Cancidas Patent Fight

Law360 (March 2, 2011, 1:15 PM EST) -- Merck & Co. Inc. on Wednesday resolved a suit in New Jersey seeking to prevent Teva Pharmaceuticals USA Inc. from marketing a generic version of anti-fungal drug Cancidas.

Judge Stanley Chesler of the U.S. District Court for the District of New Jersey dismissed Merck’s infringement action in light of the litigants' decision to settle their differences rather than proceed toward a trial this fall.

Details of the settlement remain confidential, save that each side is covering its own costs and fees racked up over roughly 15 months of litigation.

Merck accused Teva of infringing three patents covering Cancidas when it sought...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!